2020
DOI: 10.1002/14651858.cd001909.pub3
|Get access via publisher |Summarize |Cite
|
Sign up to set email alerts

Lamotrigine add-on therapy for drug-resistant focal epilepsy

Search citation statements

Order By: Relevance

Paper Sections

Select...
24
2
2
0

Citation Types

1
18
0
2

Year Published

Range
2020
2020
2026
2026

Publication Types

Select...
25
2
1

Relationship

0
28

Authors

Journals

citations

Cited by 28 publications

(21 citation statements)
references

References 63 publications

1
18
0
2
Order By: Relevance
How this paper cites the one you are viewing
“…In studies comparing the rate of PBAEs across 18 ASMs in adults [ 36 ] and in children [ 37 ] with epilepsy (mainly with DRE), LTG, one of the most frequently used ASMs, had one of the lowest rates of PBAEs and discontinuations because of PBAEs (Table S1 of the ESM). The good PBAE profile of LTG is in line with other studies [ 131 , 214 , 215 ], including the recent Cochrane systematic reviews of LTG studies in drug-resistant focal seizures and drug-resistant generalised tonic-clonic seizures where no PBAEs were among the most frequently reported (Table S1 of the ESM) [ 213 , 216 ]. Of note, LTG also acts as a mood stabiliser and is indicated for depression in patients with bipolar disorder [ 210 , 211 ].…”
Section: Additional Asms Used In the Treatment Of Lgs
supporting
confidence: 85%